Phio Pharmaceuticals (FRA:44R3) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Phio Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2024 was €-1.85 Mil. Phio Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Phio Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Phio Pharmaceuticals's current FCF Yield % is -291.87%.

The historical rank and industry rank for Phio Pharmaceuticals's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Phio Pharmaceuticals was -5452.90%. The lowest was -64780.00%. And the median was -31275.70%.

FRA:44R3's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -141.025
* Ranked among companies with meaningful FCF Margin % only.

Phio Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Phio Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals FCF Margin % Chart

Phio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-41,294.74

Phio Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Phio Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Phio Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's FCF Margin % falls into.

Phio Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Phio Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-9.862	/	0
	=	%

Phio Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.85	/	0
	=	%

Phio Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Phio Pharmaceuticals (FRA:44R3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PHIO:USA

Address

257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines